Inhibitory effects of bovine lactoferrin on intestinal polyposis in the Apc(Min) mouse

Cancer Letters

Volumn 134, Issue 2, 1998, Pages 141-145

  Ushida, Yoshihiko ^a   Sekine, Kazunori ^a   Kuhara, Tetsuya ^a   Takasuka, Nobuo ^a   Iigo, Masaaki ^a   Tsuda, Hiroyuki ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Apc; Bovine lactoferrin; Knockout mice

Indexed keywords

LACTOFERRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; GASTROINTESTINAL POLYPOSIS; HISTOPATHOLOGY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALS; ANTICARCINOGENIC AGENTS; CATTLE; DISEASE MODELS, ANIMAL; GROWTH DISORDERS; INTESTINAL MUCOSA; INTESTINAL POLYPS; LACTOFERRIN; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS;

EID: 0032417373     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00249-3     Document Type: Article

References (28)

1. Levay P.F., Viljoen M. Lactoferrin: a general review. Haematologica. 80:1995;252-267.
2. Lonnerdal B., Iyer S. Lactoferrin: molecular structure and biological function. Annu. Rev. Nutr. 15:1995;93-110.
3. Brock J. Lactoferrin: a multifunctional immunoregulatory protein? Immunol. Today. 16:1995;417-419.
4. Brock J.H. Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the newborn infant. Arch. Dis. Child. 55:1980;417-421.
5. Nishiya K., Horwitz D.A. Contrasting effects of lactoferrin on human lymphocyte and monocyte natural killer activity and antibody-dependent cell-mediated cytotoxicity. J. Immunol. 129:1982;2519-2523.
6. Shau H., Kim A., Golub S.H. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J. Leukocyte Biol. 51:1992;343-349.
7. Gahr M., Speer C.P., Damerau B., Sawatzki G. Influence of lactoferrin on the function of human polymorphonuclear leukocytes and monocytes. J. Leukocyte Biol. 49:1991;427-433.
8. Sawatzki G., Rich I.N. Lactoferrin stimulates colony stimulating factor production in vitro and in vivo. Blood Cells. 15:1989;371-385.
9. McCormick J.A., Markey G.M., Morris T.C. Lactoferrin-inducible monocyte cytotoxicity for K562 cells and decay of natural killer lymphocyte cytotoxicity. Clin. Exp. Immunol. 83:1991;154-156.
10. Sekine K., Ushida Y., Kuhara T., Iigo M., Baba-Toriyama H., Moore M.A., Murakoshi M., Satomi Y., Nishino H., Kakizoe T., Tsuda H. Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane. Cancer Lett. 121:1997;211-216.
11. Sekine K., Watanabe E., Nakamura J., Takasuka N., Kim D.J., Asamoto M., Krutovskikh V., Baba T.H., Ota T., Moore M.A., Masuda M., Sugimoto H., Nishino H., Kakizoe T., Tsuda H. Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn. J. Cancer Res. 88:1997;523-526.
12. Bezault J., Bhimani R., Wiprovnick J., Furmanski P. Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 54:1994;2310-2312.
13. Moser A.R., Pitot H.C., Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 247:1990;322-324.
14. Levy D.B., Smith K.J., Beazer B.Y., Hamilton S.R., Vogelstein B., Kinzler K.W. Inactivation of both APC alleles in human and mouse tumors. Cancer Res. 54:1994;5953-5958.
15. + in intestinal adenomas from Min mice. Cancer Res. 54:1994;5947-5952.
16. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 56:1996;710-714.
17. Tonelli F., Valanzano R., Dolara P. Sulindac therapy of colorectal polyps in familial adenomatous polyposis. Digest. Dis. 12:1994;259-264.
18. Pereira M.A., Barnes L.H., Steele V.E., Kelloff G.V., Lubet R.A. Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis. 17:1996;373-376.
19. D716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
20. Williams C.S., Luongoo C., Radhika A., Zhang T., Lamps L.W., Nanney L.B., Beauchamp R.D., Dubois R.N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. 111:1996;1134-1140.
21. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:1995;3785-3789.
22. Yoshimi N., Kawabata K., Hara A., Matsunaga K., Yamada Y., Mori H. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn. J. Cancer Res. 88:1997;1044-1051.
23. Britigan B.E., Serody J.S., Cohen M.S. The role of lactoferrin as an anti-inflammatory molecule. Adv. Exp. Med. Biol. 357:1994;143-156.
24. Elverfors J., Motas C. Anti-inflammatory capacities of human milk: lactoferrin and secretory IgA inhibit endotoxin-induced cytokine release. Adv. Exp. Med. Biol. 371A:1995;669-672.
25. Law B.A., Reiter B. The isolation and bacteriostatic properties of lactoferrin from bovine milk whey. J. Dairy Res. 44:1977;595-599.
26. Reeves P.G., Nielsen F.H., Fahey G.J. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr. 123:1993;1939-1951.
27. Reeves P.G., Rossow K.L., Lindlauf J. Development and testing of the AIN-93 purified diets for rodents: results on growth, kidney calcification and bone mineralization in rats and mice. J. Nutr. 123:1993;1923-1931.
28. Min mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res. 57:1997;812-814.